English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Aim: The collaboration between physicians and pharmaceutical industry are based on financial interests on both sides. Transparency will bring the scientific as well as social public to a position from which they are able to judge whether the physician’s interest dominates over the patients’ benefit. Proposals: The declaration of any conflicting interest (CoI) must be placed on the first slide of a scientific presentation and on the last line of a published abstract. Declaring the amount of industry funding in the patient information form of all investigatorinitiated clinical trials should also be considered. To limit influence of the industry on data presentation and interpretation, employees or experts acting in charge of a sponsoring company cannot be made co-authors but will only be mentioned in the acknowledgement of publications. For approval of a clinical trial the local ethics committee or the institutional review board should evaluate whether industrial funding is balanced by personal work. Conclusion: The need to disclose will motivate physicians to keep their own interests under control. The intrinsic motivation of the profession needs support by external oversight to maintain the ethics in physician-industry interactions. (Expenses were refunded for FK, KM and DP by ERA-EDTA.)

Physicians and Pharmaceutical Industry: Need for Transparency by Conflict of Interest Declaration and Independent Ethical Oversight